SEC Comment Letter for Altimmune, Inc. (ALT) (CIK 0001326190) (ALT) — Aug 22, 2019

Altimmune, Inc. (ALT) (CIK 0001326190)
Date: Aug. 22, 2019 · CIK: 0001326190 · Accession: 0000000000-19-012749

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-32587

Date

August 22, 2019

Author

Vipin K. Garg

Form

UPLOAD

Company

Altimmune, Inc. (ALT) (CIK 0001326190)

Letter

August 22, 2019 Vipin K. Garg Chief Executive Officer Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, Maryland, 20878 Re:Altimmune, Inc. Preliminary Proxy Statement on Schedule 14A Filed August 9, 2019 File No. 001-32587 Dear Dr. Garg: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Joseph C. Theis, Jr. - Goodwin Procter LLP

Show Raw Text

August 22, 2019
Vipin K. Garg
Chief Executive Officer
Altimmune, Inc.
910 Clopper Road, Suite 201S
Gaithersburg, Maryland, 20878
Re:Altimmune, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed August 9, 2019
File No. 001-32587
Dear Dr. Garg:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc:       Joseph C. Theis, Jr. - Goodwin Procter LLP

SecProbe.io